GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fresh2 Group Ltd (NAS:FRES) » Definitions » EV-to-EBITDA

Fresh2 Group (Fresh2 Group) EV-to-EBITDA : -0.87 (As of May. 09, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Fresh2 Group EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Fresh2 Group's enterprise value is $13.26 Mil. Fresh2 Group's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $-15.23 Mil. Therefore, Fresh2 Group's EV-to-EBITDA for today is -0.87.

The historical rank and industry rank for Fresh2 Group's EV-to-EBITDA or its related term are showing as below:

FRES' s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.2   Med: -1.78   Max: -0.35
Current: -0.87

During the past 6 years, the highest EV-to-EBITDA of Fresh2 Group was -0.35. The lowest was -10.20. And the median was -1.78.

FRES's EV-to-EBITDA is ranked worse than
100% of 454 companies
in the Biotechnology industry
Industry Median: 10.055 vs FRES: -0.87

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-09), Fresh2 Group's stock price is $0.4311. Fresh2 Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-7.960. Therefore, Fresh2 Group's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Fresh2 Group EV-to-EBITDA Historical Data

The historical data trend for Fresh2 Group's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresh2 Group EV-to-EBITDA Chart

Fresh2 Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBITDA
Get a 7-Day Free Trial - - -5.54 -1.37 -1.30

Fresh2 Group Quarterly Data
Dec17 Sep18 Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.96 -1.22 -0.46 -1.30 -2.91

Competitive Comparison of Fresh2 Group's EV-to-EBITDA

For the Biotechnology subindustry, Fresh2 Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fresh2 Group's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fresh2 Group's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Fresh2 Group's EV-to-EBITDA falls into.



Fresh2 Group EV-to-EBITDA Calculation

Fresh2 Group's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=13.263/-15.226
=-0.87

Fresh2 Group's current Enterprise Value is $13.26 Mil.
Fresh2 Group's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fresh2 Group  (NAS:FRES) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Fresh2 Group's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.4311/-7.960
=At Loss

Fresh2 Group's share price for today is $0.4311.
Fresh2 Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.960.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Fresh2 Group EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Fresh2 Group's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Fresh2 Group (Fresh2 Group) Business Description

Traded in Other Exchanges
Address
650 5TH Avenue, Street 2416, NEW YORK, NY, USA, 10019-6108
Fresh2 Group Ltd is a biotechnology company. It focuses on early cancer screening and detection. The company markets and sells a multi-cancer screening and detection test that uses its innovative patented CDA technology and its proprietary CDA device. In addition to early cancer screening and detection, its CDA technology has demonstrated the potential to assist physicians in cancer diagnosis, prognosis, and recurrence.